SRRK Overview
Upcoming Projects (SRRK)
-
Examining the Phase 3 SAPPHIRE Study Results for Apitegromab in Spinal Muscular Atrophy (SMA) from Scholar Rock (SRRK)
Ticker: SRRK
Execute By: Dec 31, 2024
Executed Projects (SRRK)
-
Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Tickers: SRRK, RHHBF, BHVN, BIIB
Executed On: Oct 10, 2024 at 03:00 PM EDT -
Discussing the use of myostatin inhibitors in SMA
Tickers: BHVN, SRRK, RHHBY
Executed On: Aug 20, 2024 at 11:00 AM EDT -
Examining the current treatment landscape and anti myostatin inhibition approaches for Spinal Muscular Atrophy (SMA) including Scholar Rock's apitegromab, Biohaven's taldefgrobep Alfa and Roche's GYM329
Tickers: SRRK, RHHBY
Executed On: Oct 25, 2023 at 08:00 AM EDT -
A third look: Discussing Scholar Rock's SMA treatment apitegromab, a selective inhibitor of the activation of latent myostatin, and the TOPAZ and SAPPHIRE trials
Ticker: SRRK
Executed On: Jul 14, 2023 at 12:30 PM EDT -
A second look: Discussing Scholar Rock's SMA treatment apitegromab, a selective inhibitor of the activation of latent myostatin, and the TOPAZ and SAPPHIRE trials
Ticker: SRRK
Executed On: Jun 12, 2023 at 04:00 PM EDT -
Discussing Scholar Rock's SMA treatment apitegromab, a selective inhibitor of the activation of latent myostatin, and the TOPAZ and SAPPHIRE trials
Ticker: SRRK
Executed On: May 09, 2023 at 10:00 AM EDT
Upcoming & Overdue Catalysts (SRRK)
-
Apitegromab Phase 3 sapphire results
Ticker: SRRK
Future Window: Oct 01, 2024 - Dec 31, 2024
Strategic Initiatives (SRRK)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
